TWI585089B - Novel condensed pyrimidine compounds or salts thereof - Google Patents

Novel condensed pyrimidine compounds or salts thereof Download PDF

Info

Publication number
TWI585089B
TWI585089B TW103127536A TW103127536A TWI585089B TW I585089 B TWI585089 B TW I585089B TW 103127536 A TW103127536 A TW 103127536A TW 103127536 A TW103127536 A TW 103127536A TW I585089 B TWI585089 B TW I585089B
Authority
TW
Taiwan
Prior art keywords
group
amino
pyrimidine
pyrazolo
zin
Prior art date
Application number
TW103127536A
Other languages
English (en)
Chinese (zh)
Other versions
TW201536786A (zh
Inventor
Satoru Iguchi
Fumihito Hosoi
Takeshi Sagara
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of TW201536786A publication Critical patent/TW201536786A/zh
Application granted granted Critical
Publication of TWI585089B publication Critical patent/TWI585089B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
TW103127536A 2013-08-12 2014-08-11 Novel condensed pyrimidine compounds or salts thereof TWI585089B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013167600 2013-08-12

Publications (2)

Publication Number Publication Date
TW201536786A TW201536786A (zh) 2015-10-01
TWI585089B true TWI585089B (zh) 2017-06-01

Family

ID=52468312

Family Applications (1)

Application Number Title Priority Date Filing Date
TW103127536A TWI585089B (zh) 2013-08-12 2014-08-11 Novel condensed pyrimidine compounds or salts thereof

Country Status (22)

Country Link
US (1) US9580432B2 (enExample)
EP (1) EP2947086B1 (enExample)
JP (1) JP6035423B2 (enExample)
KR (1) KR101828187B1 (enExample)
CN (1) CN105452257B (enExample)
AU (1) AU2014307437B2 (enExample)
BR (1) BR112016002069B1 (enExample)
CA (1) CA2921208C (enExample)
DK (1) DK2947086T3 (enExample)
ES (1) ES2661733T3 (enExample)
HU (1) HUE036834T2 (enExample)
MX (1) MX360498B (enExample)
MY (1) MY171831A (enExample)
NO (1) NO2947086T3 (enExample)
PH (1) PH12015502737B1 (enExample)
PL (1) PL2947086T3 (enExample)
PT (1) PT2947086T (enExample)
RU (1) RU2666349C2 (enExample)
SG (1) SG11201600048VA (enExample)
TR (1) TR201802875T4 (enExample)
TW (1) TWI585089B (enExample)
WO (1) WO2015022926A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014308616B2 (en) 2013-08-23 2018-12-06 Neupharma, Inc. Certain chemical entities, compositions, and methods
HUE038041T2 (hu) 2015-01-30 2018-10-29 Taiho Pharmaceutical Co Ltd Fuzionált pirimidin vegyület új sója és annak kristálya
MX381234B (es) * 2015-01-30 2025-03-12 Taiho Pharmaceutical Co Ltd Agente preventivo y/o terapéutico de enfermedad inmune.
MY191938A (en) * 2015-09-01 2022-07-19 Taiho Pharmaceutical Co Ltd Novel pyrazolo[3,4-d]pyrimidine compound or salt thereof
MA41559A (fr) * 2015-09-08 2017-12-26 Taiho Pharmaceutical Co Ltd Composé de pyrimidine condensé ou un sel de celui-ci
TWI642671B (zh) * 2015-10-28 2018-12-01 台灣神隆股份有限公司 依魯替尼之製備方法及其中間體
PL3269370T3 (pl) 2016-02-23 2020-06-01 Taiho Pharmaceutical Co., Ltd. Nowy skondensowany związek pirymidynowy lub jego sól
JP7101165B2 (ja) * 2016-08-15 2022-07-14 ニューファーマ, インコーポレイテッド 特定の化学的実体、組成物、および方法
TWI831739B (zh) * 2017-02-28 2024-02-11 日商大鵬藥品工業股份有限公司 使用吡唑并[3,4-d]嘧啶化合物之抗腫瘤效果增強劑
US12258376B2 (en) 2017-08-21 2025-03-25 Taiho Pharmaceutical Co., Ltd. Fusion protein of DCTN1 protein with RET protein
MY206124A (en) * 2019-01-11 2024-11-30 Taiho Pharmaceutical Co Ltd Pyrimidine compound or salt thereof
CN114364798A (zh) 2019-03-21 2022-04-15 欧恩科斯欧公司 用于治疗癌症的Dbait分子与激酶抑制剂的组合
US20220401436A1 (en) 2019-11-08 2022-12-22 INSERM (Institute National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
EP4079306A4 (en) * 2019-12-19 2024-01-10 Taiho Pharmaceutical Co., Ltd. THERAPEUTIC AGENT CONTAINING A PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4183395A4 (en) * 2020-07-15 2024-07-24 Taiho Pharmaceutical Co., Ltd. PYRIMIDINE COMPOUND-CONTAINING COMBINATION FOR USE IN TUMOR TREATMENT
WO2022140246A1 (en) 2020-12-21 2022-06-30 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy
CN114736207B (zh) * 2022-04-28 2023-03-31 武汉九州钰民医药科技有限公司 一种小分子her2抑制剂的制备工艺

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008054827A2 (en) * 2006-11-03 2008-05-08 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
WO2013010136A2 (en) * 2011-07-13 2013-01-17 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005042556A1 (en) 2003-10-27 2005-05-12 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections
WO2007067781A2 (en) 2005-12-08 2007-06-14 Abbott Laboratories 9-membered heterobicyclic compounds as inhibitors of protein kinases
WO2007126841A2 (en) 2006-03-29 2007-11-08 Foldrx Pharmaceuticals, Inc. Inhibition of alpha-synuclein toxicity
ES2562215T3 (es) 2007-03-28 2016-03-03 Pharmacyclics Llc Inhibidores de la tirosina quinasa de Bruton
JP2009235057A (ja) 2007-10-31 2009-10-15 Santen Pharmaceut Co Ltd 血管新生阻害活性を有する新規インドール誘導体
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
CA2986640C (en) 2008-06-27 2019-03-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CN103717247B (zh) * 2011-07-15 2016-04-27 赛诺菲-安万特德国有限公司 药物输送装置
PT2657233E (pt) 2012-01-19 2014-10-24 Taiho Pharmaceutical Co Ltd Composto de alcinil-benzeno substituído nas posições 3 e 5 e um seu sal
CN104250250A (zh) * 2013-06-25 2014-12-31 苏州科捷生物医药有限公司 4-芳香胺基嘧啶类化合物及其抗肿瘤用途

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008054827A2 (en) * 2006-11-03 2008-05-08 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
WO2013010136A2 (en) * 2011-07-13 2013-01-17 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase

Also Published As

Publication number Publication date
EP2947086A4 (en) 2016-06-22
PH12015502737B1 (en) 2018-08-31
US9580432B2 (en) 2017-02-28
WO2015022926A1 (ja) 2015-02-19
HK1217703A1 (zh) 2017-01-20
CN105452257B (zh) 2017-09-05
KR101828187B1 (ko) 2018-02-09
EP2947086A1 (en) 2015-11-25
US20160115168A1 (en) 2016-04-28
EP2947086B1 (en) 2018-01-03
RU2666349C2 (ru) 2018-09-07
KR20160038891A (ko) 2016-04-07
BR112016002069A2 (pt) 2017-08-01
JP6035423B2 (ja) 2016-11-30
TR201802875T4 (tr) 2018-03-21
PH12015502737A1 (en) 2016-03-07
PT2947086T (pt) 2018-03-09
CN105452257A (zh) 2016-03-30
RU2015156524A (ru) 2017-09-14
AU2014307437A1 (en) 2016-01-21
HUE036834T2 (hu) 2018-08-28
TW201536786A (zh) 2015-10-01
DK2947086T3 (en) 2018-03-19
MX360498B (es) 2018-11-05
NO2947086T3 (enExample) 2018-06-02
MY171831A (en) 2019-11-01
CA2921208C (en) 2018-02-20
BR112016002069B1 (pt) 2020-08-18
JPWO2015022926A1 (ja) 2017-03-02
MX2016001845A (es) 2016-05-16
CA2921208A1 (en) 2015-02-19
ES2661733T3 (es) 2018-04-03
AU2014307437B2 (en) 2016-12-15
PL2947086T3 (pl) 2018-06-29
SG11201600048VA (en) 2016-03-30

Similar Documents

Publication Publication Date Title
TWI585089B (zh) Novel condensed pyrimidine compounds or salts thereof
TWI574691B (zh) Anti - tumor agents for intermittent administration of FGFR inhibitors
TWI508964B (zh) 3,5-di-substituted phenynyl compounds and salts thereof
TW201536293A (zh) 對fgfr抑制劑具耐受性之癌的治療藥
TW201336847A (zh) 喹啉基吡咯并嘧啶化合物或其鹽
KR20200041954A (ko) 화합물, 이의 약제학적 조성물, 및 이의 용도 및 응용
TWI638817B (zh) 免疫疾病之預防及/或治療劑
TW201840568A (zh) 使用吡唑并[3,4-d]嘧啶化合物之抗腫瘤效果增強劑
HK40056552A (en) Prophylactic and/or therapeutic agent for immune diseases
HK1217703B (en) Novel fused pyrimidine compound or salt thereof
HK1240121B (zh) 免疫疾病的预防剂和/或治疗剂
HK1240121A1 (en) Prophylactic and/or therapeutic agent for immune diseases
HK1198164B (en) 3,5-disubstituted alkynylbenzene compound and salt thereof